CRISPR Shows Advantages Over Targeting PCSK9 to Treat High Cholesterol

A variation of CRISPR gene-editing technology may be a powerful way to elicit the protective effects of a genetic mutation that lowers cholesterol levels and associated risks of heart disease, according to a new study published by Circulation.
 
Individuals with mutations that cause the ANGPTL3 gene to stop functioning are known to have lower levels of blood triglycerides and low-density lipoprotein cholesterol, as well as a reduced risk of coronary heart disease. Currently, this mutation is not known to have any ill health effects, making ANGPTL3 an ideal target for novel drugs.
 
Previous studies have shown that single copies of the ANGPTL3 mutations occur in 1 out of every 250 individuals of European heritage, while individuals with 2 copies are even rarer.
 
In the new study, the authors aimed to determine whether a variation of CRISPR that does not require breaks in the DNA, called base-editing, could introduce ANGPTL3 mutations to lower cholesterol levels.
 
First, the researchers injected normal mice with base-editing therapy for the ANGPTL3 gene.
 
After 1 week, sequencing of liver samples showed a 35% editing rate with no off-target mutations, according to the study.
 
Additionally, mean levels of blood lipids were up to 30% lower among mice that underwent gene therapy compared with control animals.
 
In the second part of the study, the researchers compared plasma cholesterol and triglyceride levels for ANGPTL3 mice with those injected with a base-editing treatment for another liver gene, PCSK9.
 
 
Related Coverage: Identifying Appropriate Patients for PCSK9 Inhibitors
 
 
After 1 week, ANGPTL3 therapy resulted in a similar lowering of cholesterol but a much more significant decrease in triglycerides compared with PCSK9 therapy, according to the study.
 
Current PCSK9 inhibitors have been shown to reduce cholesterol and the risk of heart attack and stroke; however, the drugs have not been found to lower triglycerides, according to the study.
 
In the third stage of the study, the authors examined the viability of base-editing ANGPTL3 in mouse models of homozygous familial hypercholesterolemia. Targeting PCSK9 has not been very effective in this model, the authors noted.
 
After 2 weeks, treated mice had a 56% reduction in triglycerides and a 51% reduction in cholesterol compared with untreated mice, according to the study.
 
The authors are currently working to explore this treatment option in human liver cells transplanted into mice in order to determine safety and efficacy.
 
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” said lead researcher Kiran Musunuru, MD, PhD, MPH. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a 1-time CRISPR ‘vaccination’ might be ready to use in these patients within 5 years.”


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Evolocumab (Repatha) consistently reduced low-density lipoprotein cholesterol in high-risk patients over time.
A combination regimen of a CTLA4 targeted therapy and a PD-1 targeted therapy could be beneficial in treating ovarian cancer.
Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$